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then-test scores only in the item of NV (P < 0.01). This was
consistent in the additional analyses divided into the two RCT
arms on the whole. CONCLUSIONS: The results of this study
suggest that we can rely on the QOL assessment results in RCTs
without worrying too much about RS.
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OBJECTIVES: The objective of this analysis was to examine the
impact of ustekinumab on health related quality of life (HRQoL)
in psoriasis patients. METHODS: 766 patients were enrolled
in the PHOENIX I trial. Patients were randomized to placebo,
ustekinumab 45 mg, or ustekinumab 90 mg. Patients received
ustekinumab at baseline, week 4, and q12w thereafter. Patients
randomized to placebo received placebo at baseline and week 4,
and ustekinumab 45 mg or 90 mg after cross-over at week 12.
HRQoL were assessed using the SF-36 and Dermatology Life
Quality Index (DLQI). RESULTS: Baseline SF-36 and DLQI
scores were similar among treatment groups with a mean PCS
score of 47.9, mean MCS score of 49.8, and mean DLQI score of
11.5. Compared with the placebo group, patients in each usteki-
numab group had signiﬁcantly greater improvements from base-
line in both the PCS (2.0 and 3.2, vs. -0.5, p < 0.001) and MCS
scores (2.1 and 2.5 vs. -1.3, p < 0.001) at week 12. All 8 domains
of the SF-36 showed statistically signiﬁcant improvements
(p < 0.05) in the combined ustekinumab group versus placebo at
week 12. At week 12, themean change from baseline in DLQIwas
-8.0 for the 45 mg group and -8.7 for the 90 mg group versus
-0.6 for the placebo group (each p < 0.001 vs. placebo). A greater
proportion of patients in each ustekinumab group than in the
placebo group achieved a clinically meaningful improvement
in PCS and MCS scores (5-point improvement), and a DLQI
score of 0 or 1 at week 12. These improvements observed in the
ustekinumab groups were maintained through week 40. Patients
in the placebo groupwho crossed-over to ustekinumab at week 12
achieved improvements in PCS, MCS and DLQI scores at week
40 that were similar in magnitude to those observed in patients
initially randomized to ustekinumab. CONCLUSIONS: Usteki-
numab treatment signiﬁcantly improves overall and disease-
speciﬁc quality of life in moderate to severe psoriasis patients.
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OBJECTIVES: To demonstrate the pertinence of using thermal
therapy in terms of quality of life. METHODS: During the 2005
and 2006 seasons, a generic scale (SF-12) and a speciﬁc scale
(DLQI—Dermatology Life Quality Index) were ﬁlled in by each
patient when they arrived at the Avène hydrotherapy center
(consultation on arrival), at the end of the thermal therapy (week
3), but also at 3 and 6 months after the end of the therapy.
RESULTS:These results took into account the 262 questionnaires
from patients suffering from psoriasis who ﬁlled in the self-
questionnaires on arrival. The average age of the subjects was
52.2  13.8 years. The gender ratio was in favour of men (55.3%
vs 44.7%). The average age of the subjects at the time of diagnosis
was 32.1  16.9 years. 66.0% of the subjects considered that
their dermatosis had deteriorated “their daily life”, 49.6% “their
health” and 49.2% “their leisure activities”. Following the 3
weeks of treatment these feelings had strongly diminished, there
were respectively only 35.2%, 26.6%and 30.5%who thought so.
The DLQI score on arrival was 26.1  20.2; following therapy
it was 10.0  10.5. The evaluation of the DLQI score was com-
pared to the score obtained on arrival, showing a signiﬁcant
improvement in quality of life at 3 weeks, sustained improvement
at 3 months and perpetuation of the effect at 6 months (p < 0.05).
These results showa signiﬁcant improvement in themental dimen-
sion of the SF-12 (MCS-12 = 39.0 on arrival to 42.5 at following
therapy). CONCLUSIONS: This study conﬁrms the alteration in
the quality of life of patients suffering frompsoriasis and its impact
on daily life. The results conﬁrm the improvement in the patients’
quality of life following the therapy, sustained improvement at 3
months, and perpetuation at 6 months.
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OBJECTIVES: To demonstrate the pertinence of using thermal
therapy in terms of quality of life. METHODS: During the 2005
and 2006 seasons, a generic scale (SF-12) and a speciﬁc scale
(DLQI—Dermatology Life Quality Index) were ﬁlled in by each
patient when they arrived at the Avène hydrotherapy center
(consultation on arrival), at the end of the thermal therapy (week
3), but also at 3 and 6 months after the end of the therapy.
RESULTS: These initial results took into account the 174 ques-
tionnaires from patients suffering from atopic dermatitis. The
average age of the subjects was 36.4  14.7 years. The gender
ratio was largely in favour of women (70.1% vs 29.9%). The
median age of the subjects at the time of diagnosis was 16.0
years. Women were diagnosed earlier than men, with a median
diagnosis age of 8.0 years for women and 20 years for men.
72.1% of subjects considered that their dermatosis had deterio-
rated “their daily life”, 58.9% “their health” and 60.0% “their
leisure”. Following the 3 weeks of therapy these feelings had
strongly diminished, and respectively only 44.3%, 34.8% and
35.3% thought so. The DLQI score on arrival was 32.4  22.7
The evaluation of the DLQI score was compared to the DLQI
score obtained on arrival, showing a signiﬁcant improvement in
quality of life at 3 weeks sustained improvement at 3 months and
perpetuation of the effect at 6 months. No signiﬁcant improve-
ment in either the mental dimension or the physical dimension of
the SF-12 were observed. CONCLUSIONS: This study conﬁrms
the alteration in the quality of life of patients suffering from
atopic dermatitis and its impact on daily life. The results conﬁrm
the improvement in the patients’ quality of life following the
therapy, sustained improvement at three months, and perpetua-
tion at six months.
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OBJECTIVES: The objective of this project was to conduct a
cross-evaluation of the quality of life of patients suffering from
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psoriasis compared with those suffering from atopic dermatitis.
METHODS: A generic scale (SF-12), a speciﬁc scale
(DLQI—Dermatology Life Quality Index) and a daytime sleepi-
ness evaluation questionnaire (Epworth scale) were completed by
each patient when they arrived at the Avène Hydrotherapy center.
RESULTS: For the population analysed (n = 460), the average
age was respectively 37.5  14.9 years for patients suffering
from atopic dermatitis (n = 175) compared with 53.7  14.0
years fro the patients with psoriasis (n = 279). The gender ratio
was opposite, in favour of women for atopic dermatitis (70.1%)
and men for psoriasis (55.3%). The DLQI score was 29.7  19.8
for patients suffering from atopic dermatitis and 27.2  19.2 for
patients with psoriasis. The SF-12 mental dimension of patients
suffering from atopic dermatitis were more altered than that of
patients with psoriasis (38.0  6.5 versus 39.5  6.3). Patients
with psoriasis were signiﬁcantly more physically affected than
atopic patients (physical dimension component of 44.4  6.7
in patients with psoriasis compared to 45.6  5.9 in atopic
patients). Patients suffering from atopic dermatitis felt that their
disease had signiﬁcantly more often deteriorated their health
than patients with psoriasis (with respectively 58.4% versus
49.5%), but also their relationships with their children and with
the rest of their family. CONCLUSIONS: These initial results
showed an alteration in the quality of life of patients with pso-
riasis and patients suffering from atopic dermatitis and the
impact of 2 dermatoses on daily life. Patients with psoriasis were
more affected physically, unlike the atopic patients, for whom the
suffering was more mental. This notion also occurs with the
feeling of a greater deterioration of their relationship with their
children or families in atopic patients in comparison with pso-
riasis patients.
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OBJECTIVES: Evaluate QoL and self-perceived stress in a popu-
lation with atopic dermatitis. METHODS: For 5 consecutive
days, 5 dermatology departments in France handed out self-
perceived stress (PCV-Metra) and QoL questionnaires (SF12) to
patients attending their outpatient clinics. RESULTS: Of a total
658 adult patients who attended an appointment and responded
during these 5 days, 10.5% presented with atopic dermatitis
diagnosed by the dermatologist. Mean patient age was
35.6  17.0 years with more women than men (53.5% vs
46.6%). 41.1% had suffered from atopic dermatitis for less than
one year and 25.5% for 5 years and more). One in two patients
had made an appointment with their dermatologist because their
atopic dermatitis had worsened. The self-perceived stress level
was 9.1  4.3 and a sex-related bias in favour of women
(10.3  4.7 vs 7.7  3.3, p = 0.004). Patients who had suffered
from dermatosis for more than 5 years had a self-perceived stress
level of 11.6  3.8 vs 7.7  3.7 in patients with less than 5 years.
In addition, patients seeing their dermatologist because their
condition had worsened had a self-perceived stress level of
10.4  4.0 vs 9.1  4.4 in patients consulting for another
reason. The SF12 mental component score was 46.2  10.6 in
patients with recently diagnosed atopic dermatitis (not more than
5 years) vs 41.3  8.6 in those with more than 5 years. CON-
CLUSIONS: The age of the atopic dermatitis (more or less than
5 years) has a statistically signiﬁcant impact on the self-perceived
stress level (p = 0.04). Neither sex, date of diagnosis, or exacer-
bation of the atopic dermatitis had an impact on SF12 mental or
physical component scores. Atopic patients seem to suffer from
chronic stress related to the chronic nature of the dermatosis,
probably caused by exhaustion and known changes occurring in
the hypothalamus-pituitary axis.
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OBJECTIVES: Evaluate QoL and self-perceived stress in a
population with melanotic tumours. METHODS: For 5 con-
secutive days, 5 dermatology departments in France handed
out self-perceived stress (PCV-Metra) and QoL questionnaires
(SF12) to patients attending their outpatient clinics. RESULTS:
Of a total 658 adult patients who attended an appointment and
responded during these 5 days, 18% presented with a melan-
otic tumour diagnosed by the dermatologist. Mean patient age
was 52.0  17.3 years, with more women than men (56.8% vs
43.2%). A total of 41.9% had tumours discovered more than
5 years before and for 23.3% the melanotic tumour had been
discovered more recently (less than a year ago). Fifteen percent
of patients with a melanotic tumour also presented with a con-
comitant dermatological condition. The evaluation of stress via
the self-questionnaire evidenced a self-perceived stress level of
8.8  4.0. Patients who had suffered from dermatosis for more
than 5 years had a self-perceived stress level of 9.2  4.4 vs
8.9  3.5 in patients with a more recent skin condition (5 years
or less). QoL evaluated using the SF12 showed a change in the
mental component outcome with a score of 43.0  9.9 and a
physical component score of 48.2  9.4. The SF12 mental
component score was 45.0  9.3 in patients with dermatosis
arising within the last 5 years vs 40.3  10.2 in patients with
skin conditions of longer duration. CONCLUSIONS: The
mental health status is more impaired for patients whose mel-
anotic tumour had been discovered more than 5 years before
than for those with a more recent tumour (p = 0.05). The ﬁnd-
ings of this study on patients with melanotic tumours, a subject
seldom discussed in the literature, encourages us to investigate
further.
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OBJECTIVES: To evaluate the quality of life of the children
treated at the Avène hydrotherapy center and that of their
parents. METHODS: The quality of life of the children was
evaluated using the CDLQI (Children’s Dermatology Life
Quality Index) and a generic scale (SF-12) was used. The ques-
tionnaires were ﬁlled in by one of the 2 parents: when the child
arrived at the Avène hydrotherapy center (consultation on
arrival), at the end of the thermal therapy (week 3) but also at 3
and 6 months. RESULTS: Our sample involved 237 subjects on
arrival, with an average age of 10.2  3.2, 86.3% atopic and
10.7% with psoriasis. In 89% of cases it was the mother who
accompanied the child. The average age was respectively
10.1  3.2 years for the children suffering from atopic dermatitis
versus 11.3  2.8 years for the psoriasis patients. For the atopic
children, there was a signiﬁcant improvement in the CDLQI
score at 3 weeks, sustained improvement at 3 months and per-
petuation of the effect at 6 months. Regarding the SF-12, the
results are organised into 2 scores: mental (MCS-12) and physi-
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